Stephen Carey Sells 2,850 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $84.12, for a total transaction of $239,742.00. Following the transaction, the chief financial officer directly owned 177,543 shares in the company, valued at approximately $14,934,917.16. This trade represents a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Price Performance

Shares of ANIP traded down $1.33 during trading hours on Tuesday, reaching $82.78. The company had a trading volume of 238,730 shares, compared to its average volume of 391,150. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06. ANI Pharmaceuticals, Inc. has a 12-month low of $62.60 and a 12-month high of $99.50. The firm has a 50 day simple moving average of $80.70 and a 200-day simple moving average of $79.34. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of 20.96 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm had revenue of $237.46 million for the quarter, compared to the consensus estimate of $207.63 million. During the same quarter in the previous year, the firm earned $1.70 earnings per share. The firm’s revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANIP. Arrowstreet Capital Limited Partnership purchased a new stake in shares of ANI Pharmaceuticals in the third quarter valued at about $32,992,000. Balyasny Asset Management L.P. increased its stake in shares of ANI Pharmaceuticals by 2,785.7% during the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock worth $26,211,000 after purchasing an additional 276,233 shares in the last quarter. Divisadero Street Capital Management LP acquired a new position in shares of ANI Pharmaceuticals during the 3rd quarter worth approximately $21,454,000. Rubric Capital Management LP raised its position in shares of ANI Pharmaceuticals by 354.7% during the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock worth $16,813,000 after purchasing an additional 200,998 shares during the last quarter. Finally, UBS Group AG lifted its stake in ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after buying an additional 185,172 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on ANIP shares. Weiss Ratings upgraded ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Finally, Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.